Active Ingredient: Agalsidase alfa
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
0.2 - 0.2 mg per kg of body weight
From 0.2 To 0.2 mg per kg of body weight once every 14 day(s)
The safety and efficacy of agalsidase alfa in children aged 0-6 years has not yet been established.
In clinical studies of children (7-18 years) who received agalsidase alfa 0.2 mg/kg every other week, no unexpected safety issues were encountered.
Intravenous infusion over 40 minutes.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
